Moomoo AIのまとめ
On May 1, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission by Allostery Master Fund LP, Allostery Investments LP, Allostery Investments GP LLC, and individuals Christopher Staral and David Modest, collectively referred to as the Reporting Persons, indicating a collective ownership of 78,255 shares of Avalo Therapeutics, Inc. This represents approximately 7.6% of the company's outstanding common stock. The filing, made under Rule 13d-1(c), indicates that the shares are beneficially owned and that the Reporting Persons have shared voting and dispositive power over these shares. The principal business address for all Reporting Persons is in Stamford, CT. Avalo Therapeutics, Inc., the issuer, is based in Rockville, MD. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
On May 1, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission by Allostery Master Fund LP, Allostery Investments LP, Allostery Investments GP LLC, and individuals Christopher Staral and David Modest, collectively referred to as the Reporting Persons, indicating a collective ownership of 78,255 shares of Avalo Therapeutics, Inc. This represents approximately 7.6% of the company's outstanding common stock. The filing, made under Rule 13d-1(c), indicates that the shares are beneficially owned and that the Reporting Persons have shared voting and dispositive power over these shares. The principal business address for all Reporting Persons is in Stamford, CT. Avalo Therapeutics, Inc., the issuer, is based in Rockville, MD. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
2024年5月1日、Allostery Master Fund LP、Allostery Investments LP、Allostery Investments GP LLC、および Christopher Staral さんと David Modest さんの個人が集合的に報告者と呼ばれる Reporting Persons として、United States Securities and Exchange Commission に13G書式が提出されました。これにより、Avalo Therapeutics, Inc. の株式約7.6％にあたる78,255株を保有していることが明らかになり...すべて展開
2024年5月1日、Allostery Master Fund LP、Allostery Investments LP、Allostery Investments GP LLC、および Christopher Staral さんと David Modest さんの個人が集合的に報告者と呼ばれる Reporting Persons として、United States Securities and Exchange Commission に13G書式が提出されました。これにより、Avalo Therapeutics, Inc. の株式約7.6％にあたる78,255株を保有していることが明らかになりました。このファイリングは、Rule 13d-1(c)の下で行われ、これらの株式が有益所有されており、報告者がこれらの株式に対し共同する投票および取引権を有していることを示しています。報告者全員の主なビジネスアドレスは、ct(コンピュータ断層撮影)のスタンフォードにあります。発行者であるAvalo Therapeutics, Inc.はメリーランド州ロックヴィルに拠点を置いています。この書類は、これらの株式が発行体の支配力を変更または影響を与える目的で取得されたものではないと主張しています。
役に立った
役に立たない